Robert S. Landsman

Array ( [id] => 17704612 [patent_doc_number] => 20220204618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => ANTI-NKG2A ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/670398 [patent_app_country] => US [patent_app_date] => 2022-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17670398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687750 [patent_doc_number] => 20220195042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => ANTI-NKG2A ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/668807 [patent_app_country] => US [patent_app_date] => 2022-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -153 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17668807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521111 [patent_doc_number] => 12122819 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant [patent_app_type] => utility [patent_app_number] => 17/668825 [patent_app_country] => US [patent_app_date] => 2022-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 17 [patent_no_of_words] => 41073 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17668825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20192228 [patent_doc_number] => 20250268938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => SMALL MOLECULE-REGULATED CELL SIGNALING EXPRESSION SYSTEM [patent_app_type] => utility [patent_app_number] => 18/274944 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18274944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111308 [patent_doc_number] => 20240123058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => EPITOPE PEPTIDE AND ANTIBODY FOR PREVENTING AND TREATING EB VIRUS INFECTION AND RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 18/276700 [patent_app_country] => US [patent_app_date] => 2022-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27531 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 195 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18276700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987808 [patent_doc_number] => 20240059777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => MUTATIONS IN CANINE ANTIBODY CONSTANT REGIONS [patent_app_type] => utility [patent_app_number] => 18/270062 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595348 [patent_doc_number] => 20220144921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => DENGUE VIRUS NON-STRUCTURAL PROTEIN 1 SPECIFIC BINDING POLYPEPTIDES AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/583936 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20272043 [patent_doc_number] => 12441812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules [patent_app_type] => utility [patent_app_number] => 17/580980 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 86 [patent_figures_cnt] => 242 [patent_no_of_words] => 92906 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17580980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807491 [patent_doc_number] => 20220259326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER [patent_app_type] => utility [patent_app_number] => 17/580970 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17580970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638096 [patent_doc_number] => 12168697 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Bispecific antibodies which bind blood coagulation factor VIII and have enhanced activity, and methods of use thereof for treating bleeding and associated conditions [patent_app_type] => utility [patent_app_number] => 17/563149 [patent_app_country] => US [patent_app_date] => 2021-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7741 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 347 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17563149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20896494 [patent_doc_number] => 12703752 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-11 [patent_title] => Multispecific antibodies having specificity for IL-4R and IL-31, encoding nucleic acids thereof and methods of treating [patent_app_type] => utility [patent_app_number] => 18/258858 [patent_app_country] => US [patent_app_date] => 2021-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 31120 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18258858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895250 [patent_doc_number] => 20240010735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR AMYOTROPHIC LATERAL SCLEROSIS [patent_app_type] => utility [patent_app_number] => 18/029540 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641983 [patent_doc_number] => 20220169721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => Compositions and Methods for Targeting Connexin Hemichannels [patent_app_type] => utility [patent_app_number] => 17/559022 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018987 [patent_doc_number] => 20240075158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => COMPLEX OF ANTI-IL-4R ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/268104 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15375 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18268104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754020 [patent_doc_number] => 20230357386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => ANTI-EPHA4 ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/027413 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13770 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18027413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685956 [patent_doc_number] => 20220193248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => PEPTIDE-LINKED DRUG DELIVERY SYSTEM [patent_app_type] => utility [patent_app_number] => 17/556714 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18996166 [patent_doc_number] => 11912998 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Method of treating aging-associated cognitive impairment by reducing CCR3 [patent_app_type] => utility [patent_app_number] => 17/550787 [patent_app_country] => US [patent_app_date] => 2021-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 63 [patent_no_of_words] => 23276 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17550787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482164 [patent_doc_number] => 20220089668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => TARGETED MUTANT INTERFERON-BETA AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/547839 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17547839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18201218 [patent_doc_number] => 11583590 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-21 [patent_title] => Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor [patent_app_type] => utility [patent_app_number] => 17/543697 [patent_app_country] => US [patent_app_date] => 2021-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 72 [patent_no_of_words] => 109082 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17543697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482589 [patent_doc_number] => 20220090093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => METHODS FOR INDUCIBLE EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/542698 [patent_app_country] => US [patent_app_date] => 2021-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 205 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542698 [rel_patent_id] =>[rel_patent_doc_number] =>)